DICE Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

DICE Therapeutics, based in South San Francisco, has announced management's upcoming presentation at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 4:20 p.m. ET.

The company focuses on developing oral therapeutics for chronic diseases, particularly in immunology, using its proprietary DELSCAPE platform. DICE's lead candidate, S011806, targets IL-17, a molecule involved in inflammation. Interested parties can access a live and archived webcast of the presentation on their website for 90 days post-event.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the 11^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 4:20 p.m. ET.

A Live and archived webcast of the presentation can be accessed under “Events & Presentations” on the Investors section of the Company's website. The archived webcast will be available on the Company’s website for 90 days after the event.

About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Contact:
Katie Engleman, 1AB
katie@1abmedia.com

FAQ

What is DICE Therapeutics' focus at the SVB Leerink Global Healthcare Conference?

DICE Therapeutics will present its oral therapeutic candidates targeting chronic diseases, particularly in immunology.

When is DICE Therapeutics' presentation scheduled?

The presentation is scheduled for February 17, 2022, at 4:20 p.m. ET.

How can I watch DICE Therapeutics' presentation?

The presentation can be accessed live and archived on the company's website under the 'Events & Presentations' section.

What is the lead candidate being developed by DICE Therapeutics?

The lead candidate is S011806, which acts as an oral antagonist of the pro-inflammatory molecule IL-17.

What platform does DICE Therapeutics use for drug discovery?

DICE uses the DELSCAPE platform to discover selective oral small molecules targeting protein-protein interactions.